Department of Urology, the First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
PLoS One. 2013 Sep 20;8(9):e75283. doi: 10.1371/journal.pone.0075283. eCollection 2013.
Prostate cancer (PCa) remains as one of the most common cause of cancer related death among men in the US. The widely used prostate specific antigen (PSA) screening is limited by low specificity. The diagnostic value of other biomarkers such as RAS association domain family protein 1 A (RASSF1A) promoter methylation in prostate cancer and the relationship between RASSF1A methylation and pathological features or tumor stage remains to be established. Therefore, a meta-analysis of published studies was performed to understand the association between RASSF1A methylation and prostate cancer. In total, 16 studies involving 1431 cases and 565 controls were pooled with a random effect model in this investigation. The odds ratio (OR) of RASSF1A methylation in PCa case, compared to controls, was 14.73 with 95% CI = 7.58-28.61. Stratified analyses consistently showed a similar risk across different sample types and, methylation detection methods. In addition, RASSF1A methylation was associated with high Gleason score OR=2.35, 95% CI: 1.56-3.53. Furthermore, the pooled specificity for all included studies was 0.87 (95% CI: 0.72-0.94), and the pooled sensitivity was 0.76 (95% CI: 0.55-0.89). The specificity in each subgroup stratified by sample type remained above 0.84 and the sensitivity also remained above 0.60. These results suggested that RASSF1A promoter methylation would be a potential biomarker in PCa diagnosis and therapy.
前列腺癌（PCa）仍然是美国男性癌症相关死亡的最常见原因之一。广泛使用的前列腺特异性抗原（PSA）筛查受到特异性低的限制。其他生物标志物如 RAS 相关结构域家族蛋白 1A（RASSF1A）启动子甲基化在前列腺癌中的诊断价值以及 RASSF1A 甲基化与病理特征或肿瘤分期之间的关系仍有待确定。因此，进行了一项荟萃分析，以了解 RASSF1A 甲基化与前列腺癌之间的关系。在这项研究中，总共汇总了 16 项涉及 1431 例病例和 565 例对照的研究，并采用随机效应模型进行分析。与对照组相比，RASSF1A 甲基化在 PCa 病例中的比值比（OR）为 14.73，95%置信区间（CI）为 7.58-28.61。分层分析一致表明，在不同的样本类型和甲基化检测方法中，存在相似的风险。此外，RASSF1A 甲基化与高 Gleason 评分相关，OR=2.35，95%CI：1.56-3.53。此外，所有纳入研究的汇总特异性为 0.87（95%CI：0.72-0.94），汇总敏感性为 0.76（95%CI：0.55-0.89）。按样本类型分层的每个亚组的特异性均保持在 0.84 以上，敏感性也保持在 0.60 以上。这些结果表明，RASSF1A 启动子甲基化可能是 PCa 诊断和治疗的潜在生物标志物。
